-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to statistics, 14 companies will have IPOs from April 11 to 15, including 3, 6, and 1 on the Growth Enterprise Market, the Science and Technology Innovation Board, the Shenzhen Stock Exchange Main Board, the Shanghai Stock Exchange Main Board, and the Beijing Stock Exchange.
The total amount of funds raised is expected to reach 24.
5 billion yuan
.
The industry said that a number of pharmaceutical IPO companies at the meeting this week are worthy of attention
.
Among them, Nuocheng Jianhua, which will be held at the meeting on April 12, will achieve A+H dual listing if it passes smoothly
.
It is reported that Nuo Chengjian has been listed on the Hong Kong Stock Exchange in March 2020, and the net amount of funds raised is about 2.
093 billion Hong Kong dollars.
Therefore, if Nuo Chengjian Hua successfully landed in A shares this time, it will achieve A+H dual listing
.
Nuocheng Jianhua is an innovative biopharmaceutical company, focusing on areas with huge unmet clinical needs, such as oncology and autoimmune diseases, and developing drugs with breakthrough potential in the global market
.
According to the prospectus, Nuocheng Jianhua plans to raise 4 billion yuan on the Science and Technology Innovation Board for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, informatization construction projects and supplementary working capital
.
If the listing is successful, Nuocheng Jianhua has accumulated financing of about 10 billion yuan since its establishment
.
From the perspective of performance, from 2019 to 2021, Nuocheng Jianhua achieved revenue of 1.
247 million yuan, 1.
3636 million yuan, and 1.
043 billion yuan respectively; net profit was -2.
141 billion yuan, -391 million yuan and -645.
46 billion yuan, respectively.
Not yet profitable
.
From the perspective of research and development results, as of the signing date of the new prospectus (April 2022), Nuocheng Jianhua has only one product approved for commercial sales - orelabrutinib, and the commercialization of this product is still in its infancy.
.
In addition, considering the entire R&D pipeline, Nuocheng Jianhua has 9 products in Phase I/II/III clinical trials and 6 products in preclinical stage
.
Another company that has attracted attention in the industry is United Imaging Medical, which will hold a meeting on April 15
.
It is reported that United Imaging Medical plans to raise up to 12.
48 billion yuan, of which 6.
168 billion yuan will be used for next-generation product research and development projects, 3.
126 billion yuan will be used for high-end medical imaging equipment industrialization fund projects, and 735 million yuan will be used for marketing service network projects.
452 million yuan will be used for informatization improvement projects, and 2 billion yuan will be used to supplement working capital
.
.
According to the data, United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions
.
The product line covers Magnetic Resonance Imaging (MR), X-ray Computed Tomography (CT), X-ray Imaging (XR), Molecular Imaging (MI), Radiation Therapy (RT) and life science instruments
.
The prospectus shows that from 2019 to 2021, United Imaging Medical achieved revenue of 2.
98 billion yuan, 5.
761 billion yuan, and 7.
254 billion yuan respectively; net profits were -48.
05 million yuan, 937 million yuan, and 1.
4 billion yuan respectively; net profit after deduction They were -255 million yuan, 878 million yuan, and 1.
166 billion yuan respectively
.
According to the manual, United Imaging has more than 2,000 R&D personnel, accounting for more than 35% of the total number of employees
.
Since its listing, the company's products have entered nearly 900 tertiary hospitals across the country
.
As of the end of the reporting period, United Imaging has launched more than 80 products to the market, including Magnetic Resonance Imaging (MR), X-ray Computed Tomography (CT), X-ray Imaging (XR), Molecular Imaging System (PET/CT) , PET/MR), medical linear accelerator systems (RT), and life science instruments
.
In the field of digital diagnosis and treatment, based on the system architecture of United Imaging Cloud, the company provides United Imaging medical cloud services, realizes cloud collaboration between equipment and applications and sharing of medical resources, and provides comprehensive solutions for end customers
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
The total amount of funds raised is expected to reach 24.
5 billion yuan
.
The industry said that a number of pharmaceutical IPO companies at the meeting this week are worthy of attention
.
Among them, Nuocheng Jianhua, which will be held at the meeting on April 12, will achieve A+H dual listing if it passes smoothly
.
It is reported that Nuo Chengjian has been listed on the Hong Kong Stock Exchange in March 2020, and the net amount of funds raised is about 2.
093 billion Hong Kong dollars.
Therefore, if Nuo Chengjian Hua successfully landed in A shares this time, it will achieve A+H dual listing
.
Nuocheng Jianhua is an innovative biopharmaceutical company, focusing on areas with huge unmet clinical needs, such as oncology and autoimmune diseases, and developing drugs with breakthrough potential in the global market
.
According to the prospectus, Nuocheng Jianhua plans to raise 4 billion yuan on the Science and Technology Innovation Board for new drug research and development projects, drug research and development platform upgrade projects, marketing network construction projects, informatization construction projects and supplementary working capital
.
If the listing is successful, Nuocheng Jianhua has accumulated financing of about 10 billion yuan since its establishment
.
From the perspective of performance, from 2019 to 2021, Nuocheng Jianhua achieved revenue of 1.
247 million yuan, 1.
3636 million yuan, and 1.
043 billion yuan respectively; net profit was -2.
141 billion yuan, -391 million yuan and -645.
46 billion yuan, respectively.
Not yet profitable
.
From the perspective of research and development results, as of the signing date of the new prospectus (April 2022), Nuocheng Jianhua has only one product approved for commercial sales - orelabrutinib, and the commercialization of this product is still in its infancy.
.
In addition, considering the entire R&D pipeline, Nuocheng Jianhua has 9 products in Phase I/II/III clinical trials and 6 products in preclinical stage
.
Another company that has attracted attention in the industry is United Imaging Medical, which will hold a meeting on April 15
.
It is reported that United Imaging Medical plans to raise up to 12.
48 billion yuan, of which 6.
168 billion yuan will be used for next-generation product research and development projects, 3.
126 billion yuan will be used for high-end medical imaging equipment industrialization fund projects, and 735 million yuan will be used for marketing service network projects.
452 million yuan will be used for informatization improvement projects, and 2 billion yuan will be used to supplement working capital
.
.
According to the data, United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions
.
The product line covers Magnetic Resonance Imaging (MR), X-ray Computed Tomography (CT), X-ray Imaging (XR), Molecular Imaging (MI), Radiation Therapy (RT) and life science instruments
.
The prospectus shows that from 2019 to 2021, United Imaging Medical achieved revenue of 2.
98 billion yuan, 5.
761 billion yuan, and 7.
254 billion yuan respectively; net profits were -48.
05 million yuan, 937 million yuan, and 1.
4 billion yuan respectively; net profit after deduction They were -255 million yuan, 878 million yuan, and 1.
166 billion yuan respectively
.
According to the manual, United Imaging has more than 2,000 R&D personnel, accounting for more than 35% of the total number of employees
.
Since its listing, the company's products have entered nearly 900 tertiary hospitals across the country
.
As of the end of the reporting period, United Imaging has launched more than 80 products to the market, including Magnetic Resonance Imaging (MR), X-ray Computed Tomography (CT), X-ray Imaging (XR), Molecular Imaging System (PET/CT) , PET/MR), medical linear accelerator systems (RT), and life science instruments
.
In the field of digital diagnosis and treatment, based on the system architecture of United Imaging Cloud, the company provides United Imaging medical cloud services, realizes cloud collaboration between equipment and applications and sharing of medical resources, and provides comprehensive solutions for end customers
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.
